David Briones - Hoth Therapeutics Chief Officer
| HOTH Stock | USD 0.83 0 0.12% |
Insider
David Briones is Chief Officer of Hoth Therapeutics
| Age | 48 |
| Address | 590 Madison Avenue, New York, NY, United States, 10022 |
| Phone | 646 756 2997 |
| Web | https://hoththerapeutics.com |
Hoth Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4616) % which means that it has lost $0.4616 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8341) %, meaning that it created substantial loss on money invested by shareholders. Hoth Therapeutics' management efficiency ratios could be used to measure how well Hoth Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.87. The current Return On Capital Employed is estimated to decrease to -0.91. The Hoth Therapeutics' current Net Tangible Assets is estimated to increase to about 11.9 M, while Total Assets are projected to decrease to under 5.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| MD MBA | Kiora Pharmaceuticals | 50 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Xiaoqin MD | Avenue Therapeutics | 49 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Jonathan Rothbard | 180 Life Sciences | 71 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Quan Vu | 180 Life Sciences | 52 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Frank Kondrad | Neurobo Pharmaceuticals | N/A | |
| Joan Brown | Allarity Therapeutics | 70 | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| Raphael Mechoulam | 180 Life Sciences | N/A | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Matthew Shatzkes | Aditxt Inc | N/A | |
| CPA CPA | Aditxt Inc | 56 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
Management Performance
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.46 |
Hoth Therapeutics Leadership Team
Elected by the shareholders, the Hoth Therapeutics' board of directors comprises two types of representatives: Hoth Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hoth. The board's role is to monitor Hoth Therapeutics' management team and ensure that shareholders' interests are well served. Hoth Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hoth Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robb Knie, President, Founder | ||
| Jane Springer, VP Operations | ||
| Hayley Springer, Executive Operations | ||
| Stefanie Johns, Chief Officer | ||
| David Briones, Chief Officer |
Hoth Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hoth Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | (2.28 M) | ||||
| Shares Outstanding | 6.9 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 4.83 % | ||||
| Number Of Shares Shorted | 620.78 K | ||||
| Price To Earning | (7.16) X | ||||
| Price To Book | 0.76 X | ||||
| EBITDA | (153.15 K) |
Currently Active Assets on Macroaxis
When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Return On Assets (0.46) | Return On Equity (0.83) |
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.